Peer-reviewedLicence not statedCell death and differentiation
Renal cell carcinoma: molecular understanding and therapeutic development
4 affiliations
- 1Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
- 2Department of Dermatology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA.
- 3Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
- 4Department of Medicine, Harvard Medical School, Boston, MA, USA.
Related
- ATG16L2 as a prognostic biomarker and therapeutic target in kidney renal clear cell carcinoma
- REDD1 in Clear Cell Renal Cell Carcinoma: Linking Stress Adaptation, Proteostasis and Therapeutic Resistance
- Clinicopathological and molecular comparison of eosinophilic solid and cystic renal cell carcinoma and TFEB ‐amplified renal cell carcinoma: a comprehensive study of 15 cases
- Spatial architecture shapes programmed cell death-associated immune niches and therapeutic resistance in clear cell renal cell carcinoma
- Sodium–Glucose Cotransporter 2-Mediated Glucose Uptake Contributes to Glycogen Accumulation in Clear Cell Renal Cell Carcinoma: Implications for Clear Cell Morphology and Potential Therapeutic Relevance
BibTeX
@article{hou2026renal,
title = {{Renal cell carcinoma: molecular understanding and therapeutic development}},
author = {Tao Hou and Xiangmei Hua and Wei Ni and Peiqiang Yan and Hiroyuki Inuzuka and Wenyi Wei},
journal = {Cell death and differentiation},
year = {2026},
month = sep,
doi = {10.1038/s41418-026-01857-9},
url = {https://doi.org/10.1038/s41418-026-01857-9},
}
RIS
TY - JOUR
TI - Renal cell carcinoma: molecular understanding and therapeutic development
AU - Tao Hou
AU - Xiangmei Hua
AU - Wei Ni
AU - Peiqiang Yan
AU - Hiroyuki Inuzuka
AU - Wenyi Wei
PY - 2026
DA - 2026/09/02
JO - Cell death and differentiation
DO - 10.1038/s41418-026-01857-9
UR - https://doi.org/10.1038/s41418-026-01857-9
SN - 1350-9047
SN - 1476-5403
ER -